CompletedPhase 1ketamine
Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects
Sponsored by AstraZeneca
NCT ID
NCT01046630
Target Enrollment
128 participants
Start Date
2009-12
Est. Completion
2011-03
About This Study
The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in depressed subjects.
Conditions Studied
Interventions
- •AZD6765
- •Ketamine
- •Placebo
Eligibility
Age:18 Years - 45 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria: * Documented clinical diagnosis meeting criteria from the DSM-IV by structured clinical interview,major depressive disorder, single episode or recurrent * Outpatient status at screening and at randomisation Exclusion Criteria: * A major depression disorder which has a major impact on the subjects current psychiatric status * Subjects not allowed to use mood stabilizers, antidepressants or other antipsychotic or psychoactive drugs * Subjects with lifetime history of schizophrenia, bi-polar, psychosis and psychotic depression
Study Locations (2)
Research Site
Manchester, United Kingdom
Research Site
Oxford, United Kingdom